Trevi Therapeutics, Inc. (TRVI)

Market Cap	1.64B +149.8%
Revenue (ttm)	n/a
Net Income	-42.76M
EPS	-0.32
Shares Out	128.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,804,220
Open	11.90
Previous Close	11.94
Day's Range	11.68 - 13.06
52-Week Range	4.85 - 14.39
Beta	1.00
Analysts	Strong Buy
Price Target	21.55 (+68.23%)
Earnings Date	May 7, 2026

About TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory ch...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2019
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: TRVI
• Website: https://www.trevitherapeutics.com

Analyst Summary

According to 11 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price target is $21.55, which is an increase of 68.23% from the latest price.

Price Target

$21.55

(68.23% upside)

Analyst Consensus: Strong Buy